NCT03005418Phase 2, phase 3Completed

Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma

Study sponsor: Humacyte, Inc. · HUMA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-09-19Actual
Enrollment · participants72Actual
Source updated2026-07-29Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: ATEV Primary Patency - Extremity Group (Non-iatrogenic) Measure: Rate of ATEV Infection - Extremity Group (Non-iatrogenic) Measure: Number of Participants With Adverse Events for Each Severity Grade - Extremity Group (Non-iatrogenic). After: Measure: Primary Patency Rate of the Human Acellular Vessel (HAV) at Day 30 in the All HAV Group Measure: Primary Patency Rate of the Human Acellular Vessel (HAV) at Day 30 in the Extremity Community-Acquired Trauma Subgroup.

Actual enrollment increased by 21 participants

Before: 51 participants (actual). After: 72 participants (actual).

Primary completion date changed

Before: 30 Jun 2023. After: 19 Sep 2023.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview